Identification

Name
Diphenhydramine
Accession Number
DB01075  (APRD00587, DB06975)
Type
Small Molecule
Groups
Approved, Investigational
Description

Diphenhydramine, also known commercially as Benadryl, is a first generation antihistamine that is used primarily for the treatment of seasonal allergies. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system. While its use in in allergies has largely fallen out of favour due to this sedative effect, diphenhydramine has been repurposed for use within many OTC (over the counter) cough-and-cold medications that have been marketed for "night time" use.

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system [4].

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid [3]. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Structure
Thumb
Synonyms
  • 2-(Benzhydryloxy)-N,N-dimethylethylamine
  • 2-diphenylmethoxy-N,N-demthylethanamine
  • alpha-(2-Dimethylaminoethoxy)diphenylmethane
  • beta-Dimethylaminoethanol diphenylmethyl ether
  • beta-Dimethylaminoethyl benzhydryl ether
  • Difenhidramina
  • Diphenhydraminum
  • N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
  • O-benzhydryldimethylaminoethanol
  • β-dimethylaminoethyl benzhydryl ether
Product Ingredients
IngredientUNIICASInChI Key
Diphenhydramine citrate4OD433S20988637-37-0SPCKHVPPRJWQRZ-UHFFFAOYSA-N
Diphenhydramine hydrochlorideTC2D6JAD40147-24-0PCHPORCSPXIHLZ-UHFFFAOYSA-N
Diphenhydramine methylbromideUJO67AO8YI31065-89-1BDQPXVWYFLTETB-UHFFFAOYSA-M
Diphenhydramine salicylate707L3YC54L7491-10-3RTSZUSOHOIFYSY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Benadryl Inj. 50mg/mlLiquid50 mgIntramuscular; IntravenousWarner Lambert Canada Inc.1994-12-312000-11-27Canada
Diphenhydramine HCl Inj USP 50mg/mlLiquid50 mgIntravenousInternational Medication Systems, Limited1974-12-311997-08-15Canada
Diphenhydramine HCl Injection, USPSolution50 mgIntramuscular; IntravenousSterimax Inc1994-12-31Not applicableCanada
Diphenhydramine Hydrochloride InjectionSolution50 mgIntramuscular; IntravenousFresenius Kabi2012-02-17Not applicableCanada
Diphenhydramine Hydrochloride Injection USPLiquid50 mgIntramuscular; IntravenousSandoz Canada Incorporated1983-12-31Not applicableCanada
Diphenist 50mg/mlLiquid50 mgIntramuscular; IntravenousOmega Laboratories Ltd1997-10-28Not applicableCanada
Scheinpharm Diphenhydramine Inj.50mg/mlSolution50 mgIntramuscular; IntravenousSchein Pharmaceutical Canada Inc.1996-09-302004-07-26Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diphendydramine HydrochlorideCapsule25 mg/1OralRemedy Repack2010-12-172017-06-20Us66424 0020 01 nlmimage10 1a038d6c
DiphenhydramineInjection, solution50 mg/mLIntravenousRemedy Repack2013-06-132017-01-24Us
DiphenhydramineInjection, solution50 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, Inc.2002-08-01Not applicableUs
Diphenhydramine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousRebel Distributors1972-11-27Not applicableUs
Diphenhydramine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1972-11-27Not applicableUs
Diphenhydramine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousSina Health Inc1972-11-27Not applicableUs
Diphenhydramine HydrochlorideElixir25 mg/10mLOralCardinal Health1982-02-102018-07-10Us
Diphenhydramine HydrochlorideInjection, solution50 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2017-06-13Not applicableUs
Diphenhydramine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousDispensing Solutions, Inc.1972-11-27Not applicableUs
Diphenhydramine HydrochlorideInjection50 mg/mLIntramuscular; IntravenousRemedy Repack2018-03-29Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select AllergyTablet25 mg/1Oral7 Eleven2014-04-22Not applicableUs
7 Select Allergy ChildrensSolution12.5 mg/5mLOral7 Eleven2014-08-05Not applicableUs
7 Select Night Time Sleep AidSolution50 mg/30mLOral7 Eleven2014-04-22Not applicableUs
Adult AllergySolution50 mg/20mLOralChain Drug Consortium2015-05-04Not applicableUs
Adult Allergy ReliefSolution50 mg/20mLOralWalmart Stores2017-05-03Not applicableUs
After Bite OutdoorGel20 mg/gTopicalTender Corporation2018-03-01Not applicableUs
After Bite OutdoorGel20 mg/mLTopicalTender Corporation2016-11-012018-03-08Us
After Bite PlusGel20 mg/gTopicalTender Corporation2018-03-01Not applicableUs
After Bite PlusCream20 mg/mLTopicalTender Corporation2012-07-032018-03-08Us
After Bite XtraGel20 mg/mLTopicalTender Corporation2016-11-012018-03-08Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Ibuprofen PMDiphenhydramine citrate (38 mg/1) + Ibuprofen (200 mg/1)Tablet, film coatedOral7 Eleven2014-08-05Not applicableUs
7 Select Night Time Severe Cold Cough and FluDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) + Phenylephrine hydrochloride (10 mg/1)Powder, for solutionOral7 Eleven2016-01-25Not applicableUs
7 Select Night Time severe cold, cough and fluDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (650 mg/1) + Phenylephrine hydrochloride (10 mg/1)Powder, for solutionOral7 Eleven2015-11-122018-03-29Us
7 Select Pain Relief PMDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1)Tablet, film coatedOral7 Eleven2014-09-042017-11-22Us
7-Select Advil PMDiphenhydramine citrate (38 mg/1) + Ibuprofen (200 mg/1)Tablet, coatedOralLil' Drug Store Products, Inc.2011-06-012017-12-31Us
Aceta-gesicDiphenhydramine hydrochloride (12.5 mg/1) + Acetaminophen (325 mg/1)Tablet, coatedOralRemedy Repack2014-08-08Not applicableUs
Aceta-gesicDiphenhydramine hydrochloride (12.5 mg/1) + Acetaminophen (325 mg/1)Tablet, coatedOralRugby2014-06-30Not applicableUs
AcetadrylDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1)Tablet, film coatedOralPhysicians Science & Nature Inc.2011-07-212017-11-30Us
AcetadrylDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1)Tablet, film coatedOralAidarex Pharmaceuticals LLC2011-07-21Not applicableUs
Acetaminophen / Diphenhydramine 500/25 mgDiphenhydramine hydrochloride (25 mg/1) + Acetaminophen (500 mg/1)TabletOralReliable 1 Laboratories2015-11-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AiracofDiphenhydramine hydrochloride (12.5 mg/5mL) + Codeine phosphate (7.5 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralCenturion Labs2010-01-082016-10-13Us
Antiphlamine Coin PlasterDiphenhydramine (.246 mg/.2832g) + Camphor (1.108 mg/.2832g) + Menthol (2.769 mg/.2832g)PatchTopicalHanul Trading Co., Ltd.2016-10-102017-02-11Us
Antiphlamine Coin PlasterDiphenhydramine (.246 mg/.2832g) + DL-alpha-Tocopherol (.308 mg/.2832g) + Menthol (2.769 mg/.2832g) + Methyl salicylate (5.541 mg/.2832g) + Nonivamide (.046 mg/.2832g) + Peppermint oil (.693 mg/.2832g) + Synthetic Camphor (1.108 mg/.2832g)PatchTopicalHanul Trading Co., Ltd.2016-10-10Not applicableUs
Contrast Allergy PreMed PackDiphenhydramine + PrednisoneKitShertech Laboratories, Llc2016-09-13Not applicableUs
DicopanolDiphenhydramine hydrochlorideKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
DicopanolDiphenhydramine hydrochlorideKitOralFusion Pharmaceuticals LLC2010-02-08Not applicableUs
Diphenhydramine HClDiphenhydramine hydrochloride (25 mg/1)CapsuleOralCardinal Health2011-06-032017-07-18Us
Diphenhydramine HClDiphenhydramine hydrochloride (25 mg/1)TabletOralCardinal Health2011-06-032018-05-31Us
FIRST Dukes Mouthwash CompoundingDiphenhydramine hydrochloride + Hydrocortisone + NystatinKitOralCutis Pharma, Inc.2010-12-152017-10-04Us
FIRST Marys Mouthwash CompoundingDiphenhydramine hydrochloride + Hydrocortisone + Nystatin + Tetracycline hydrochlorideKitOralCutis Pharma, Inc.2010-12-152017-10-04Us
International/Other Brands
Aleryl / Alledryl / Allerdryl (Valeant) / Baramine / Beldin / Belix / Benylan (Biogen) / Dermodrin (Montavit) / Desentol (Meda) / Dibondrin (Montavit) / Dimedrol (Zdorovie) / Diphen (Wockhardt) / Dormarex 2 / Genahist / Histaxin (Meda) / Hyrexin (Hyrex) / Nytol Quickgels (GlaxoSmithKline) / Restamin (Kowa Souyaku) / Siladryl / Silphen Cough
Categories
UNII
8GTS82S83M
CAS number
58-73-1
Weight
Average: 255.3547
Monoisotopic: 255.162314299
Chemical Formula
C17H21NO
InChI Key
ZZVUWRFHKOJYTH-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
IUPAC Name
[2-(diphenylmethoxy)ethyl]dimethylamine
SMILES
CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of symptoms associated with Vertigo/Meniere's disease, nausea and vomiting, motion sickness and insect bite.

Associated Conditions
Pharmacodynamics

Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.

Mechanism of action

Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption

Quickly absorbed with maximum activity occurring in approximately one hour.

Volume of distribution
Not Available
Protein binding

98 to 99%

Metabolism

Hepatic and renal

Route of elimination

Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.

Half life

1-4 hours

Clearance
Not Available
Toxicity

LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Diphenhydramine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
1,10-PhenanthrolineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Abexinostat.Investigational
AcebutololThe metabolism of Acebutolol can be decreased when combined with Diphenhydramine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aclidinium.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Acrivastine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Adipiplon.Investigational
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Diphenhydramine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Agomelatine.Approved, Investigational
Ajulemic acidThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Ajulemic acid.Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Alcaftadine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Diphenhydramine.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Diphenhydramine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenhydramine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Diphenhydramine.Approved, Withdrawn
AmantadineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Ambenonium.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Amifampridine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Anagrelide.Approved
AniracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aniracetam.Experimental
AnisodamineThe metabolism of Anisodamine can be decreased when combined with Diphenhydramine.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Anisotropine Methylbromide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Antazoline.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Diphenhydramine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Arbekacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Arformoterol.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe metabolism of Arotinolol can be decreased when combined with Diphenhydramine.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Diphenhydramine.Approved, Investigational
AtenololThe metabolism of Atenolol can be decreased when combined with Diphenhydramine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Diphenhydramine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Azatadine.Approved
AZD-3043The risk or severity of adverse effects can be increased when Diphenhydramine is combined with AZD-3043.Investigational
AzelastineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Baclofen.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbituric acid derivative.Experimental, Illicit
BeclamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Beclamide.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Bedaquiline.Approved
BefunololThe metabolism of Befunolol can be decreased when combined with Diphenhydramine.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Diphenhydramine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Diphenhydramine.Approved
BenziloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzilone.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Diphenhydramine is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzquinamide.Withdrawn
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Diphenhydramine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDiphenhydramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Diphenhydramine.Approved, Investigational
BetaxololThe metabolism of Betaxolol can be decreased when combined with Diphenhydramine.Approved, Investigational
BevantololThe metabolism of Bevantolol can be decreased when combined with Diphenhydramine.Approved
BevoniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Bilastine.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Diphenhydramine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Diphenhydramine.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Diphenhydramine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Diphenhydramine.Approved
BL-1020The risk or severity of adverse effects can be increased when Diphenhydramine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Blonanserin.Approved, Investigational
BopindololThe metabolism of Bopindolol can be decreased when combined with Diphenhydramine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Diphenhydramine.Experimental
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Diphenhydramine.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Diphenhydramine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe metabolism of Bucindolol can be decreased when combined with Diphenhydramine.Investigational
BuclizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Buclizine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bufotenine.Experimental, Illicit
BufuralolThe metabolism of Bufuralol can be decreased when combined with Diphenhydramine.Experimental, Investigational
BupranololThe metabolism of Bupranolol can be decreased when combined with Diphenhydramine.Approved
BuprenorphineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bupropion.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Buserelin.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Diphenhydramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenhydramine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenhydramine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Butriptyline.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CamazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Camylofin.Experimental
CannabidiolThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenhydramine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Carbinoxamine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Diphenhydramine.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Caroxazone.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Diphenhydramine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Diphenhydramine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Diphenhydramine.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cathinone.Illicit
CeliprololThe metabolism of Celiprolol can be decreased when combined with Diphenhydramine.Approved, Investigational
CeritinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Chlorcyclizine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Diphenhydramine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Diphenhydramine.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorphenoxamine.Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Diphenhydramine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Diphenhydramine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorzoxazone.Approved
CholineThe serum concentration of Choline can be increased when it is combined with Diphenhydramine.Approved, Nutraceutical
Choline salicylateThe serum concentration of Choline salicylate can be increased when it is combined with Diphenhydramine.Approved, Nutraceutical
CilostazolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Diphenhydramine.Approved, Investigational
CimetropiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cimetropium.Experimental, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cinnarizine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cinolazepam.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Diphenhydramine.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clopenthixol.Experimental
CloranololThe metabolism of Cloranolol can be decreased when combined with Diphenhydramine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenhydramine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Diphenhydramine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Colistin.Approved
CoumaphosThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Coumaphos.Vet Approved
CP-945598The risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with CP-945598.Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with CUDC-907.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenhydramine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Diphenhydramine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenhydramine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cycrimine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyproheptadine.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dabrafenib.Approved, Investigational
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Diphenhydramine.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Darifenacin.Approved, Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Deanol.Experimental
DecamethoniumThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Decamethonium.Approved
DegarelixThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Delamanid.Approved, Investigational
DelorazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Delorazepam.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dexchlorpheniramine maleate.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Diphenhydramine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexmedetomidine.Approved, Vet Approved
DextofisopamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Diphenhydramine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dichloralphenazone.Approved, Illicit
DichlorvosThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenhydramine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Illicit
DifemerineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Difemerine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Difenoxin.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Difloxacin.Vet Approved
DihexyverineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihexyverine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimetindene.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphemanil.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenidolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Diphenoxylate.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Disopyramide.Approved
DistigmineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Distigmine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Diphenhydramine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Donepezil.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Diphenhydramine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Diphenhydramine.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dyclonine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ebastine.Approved, Investigational
EchothiophateThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Edivoxetine.Investigational
EdrophoniumThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Efavirenz.Approved, Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Diphenhydramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Diphenhydramine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Eltanolone.Investigational
EluxadolineThe risk or severity of constipation can be increased when Diphenhydramine is combined with Eluxadoline.Approved, Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Emedastine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Enoxacin.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Entacapone.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Entinostat.Investigational
EpanololThe metabolism of Epanolol can be decreased when combined with Diphenhydramine.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Epinastine.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Diphenhydramine.Approved, Vet Approved
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Diphenhydramine.Experimental
EribulinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe metabolism of Esatenolol can be decreased when combined with Diphenhydramine.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Esmirtazapine.Investigational
EsmololThe metabolism of Esmolol can be decreased when combined with Diphenhydramine.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenhydramine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etacrynic acid.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etanautine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethadione.Experimental
EthanolDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Diphenhydramine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etybenzatropine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fabomotizole.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Diphenhydramine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenpiveriniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fenpiverinium.Experimental
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Diphenhydramine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Fenthion.Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fenyramidol.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fingolimod.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Diphenhydramine.Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fleroxacin.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Diphenhydramine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fludiazepam.Approved, Illicit
FlumequineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Flumequine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diphenhydramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenhydramine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Diphenhydramine.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Diphenhydramine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Framycetin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenhydramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gaboxadol.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Gadobenic acid.Approved, Investigational
GalantamineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gallamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gantacurium Chloride.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Gatifloxacin.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gedocarnil.Experimental
GemifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GivinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Givinostat.Investigational
Glucagon recombinantDiphenhydramine may increase the gastrointestinal motility reducing activities of Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Diphenhydramine.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Guanfacine.Approved, Investigational
GW842166The risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with GW842166.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexocyclium.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Diphenhydramine.Approved, Investigational
HistrelinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Histrelin.Approved
HomatropineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Homatropine.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Homatropine Methylbromide.Approved
Huperzine AThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diphenhydramine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Diphenhydramine.Approved, Vet Approved
HydrocodoneDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Diphenhydramine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Diphenhydramine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hyoscyamine.Approved
HypericinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hypericin.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diphenhydramine.Approved, Investigational
IbipinabantThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Ibipinabant.Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ibutilide.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IloperidoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Imagabalin.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Imatinib.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Imidafenacin.Approved, Investigational
ImipramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Imipramine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Imipramine oxide.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Diphenhydramine.Approved
IndenololThe metabolism of Indenolol can be decreased when combined with Diphenhydramine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Diphenhydramine.Approved
IpidacrineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ipratropium.Approved
IprindoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Diphenhydramine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsopropamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Isopropamide.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Diphenhydramine.Approved, Investigational
ItoprideThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Itopride.Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Itraconazole.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Diphenhydramine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ketotifen.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Diphenhydramine.Approved
LacosamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Diphenhydramine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Diphenhydramine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Diphenhydramine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lamotrigine.Approved, Investigational
LandiololThe metabolism of Landiolol can be decreased when combined with Diphenhydramine.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lanicemine.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lapatinib.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levetiracetam.Approved, Investigational
LevobetaxololThe metabolism of Levobetaxolol can be decreased when combined with Diphenhydramine.Approved, Investigational
LevobunololThe metabolism of Levobunolol can be decreased when combined with Diphenhydramine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenhydramine.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Diphenhydramine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Diphenhydramine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Diphenhydramine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lormetazepam.Approved
LortalamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenhydramine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diphenhydramine.Approved, Investigational
LumateperoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Diphenhydramine.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium chloride.Approved
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Diphenhydramine.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Diphenhydramine.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium orotate.Experimental
Magnesium oxideThe therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Diphenhydramine.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Diphenhydramine.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Diphenhydramine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Malathion.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Diphenhydramine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Maprotiline.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mazaticol.Experimental
MazindolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mebanazine.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mebeverine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Melperone.Approved, Investigational
MemantineThe serum concentration of Memantine can be increased when it is combined with Diphenhydramine.Approved, Investigational
MepenzolateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mepenzolate.Approved
MephedroneMephedrone may decrease the sedative and stimulatory activities of Diphenhydramine.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mephenoxalone.Experimental
MephentermineMephentermine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mephenytoin.Investigational, Withdrawn
MepindololThe metabolism of Mepindolol can be decreased when combined with Diphenhydramine.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mequitazine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone.Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Diphenhydramine.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methantheline.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenhydramine.Approved
MethotrimeprazineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methscopolamine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Diphenhydramine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Diphenhydramine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylpentynol.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylscopolamine bromide.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methyprylon.Approved, Illicit, Withdrawn
MetipranololThe metabolism of Metipranolol can be decreased when combined with Diphenhydramine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Diphenhydramine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Diphenhydramine.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Diphenhydramine.Approved
MetyrosineDiphenhydramine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Diphenhydramine.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Diphenhydramine.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphenhydramine.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Investigational
MirabegronThe risk or severity of urinary retention can be increased when Diphenhydramine is combined with Mirabegron.Approved
MirtazapineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mivacurium.Approved
MMDAMMDA may decrease the sedative and stimulatory activities of Diphenhydramine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Moclobemide.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Diphenhydramine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenhydramine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Mosapramine.Experimental
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Moxifloxacin.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Diphenhydramine is combined with MRK-409.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Nabiximols.Approved, Investigational
NadololThe metabolism of Nadolol can be decreased when combined with Diphenhydramine.Approved
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Diphenhydramine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Diphenhydramine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Nalidixic Acid.Approved, Investigational
NaltrexoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Naltrexone.Approved, Investigational, Vet Approved
NeamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Neamine.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Diphenhydramine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Nemonoxacin.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Neosaxitoxin.Investigational
NeostigmineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nicomorphine.Experimental
NifedipineThe metabolism of Nifedipine can be decreased when combined with Diphenhydramine.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nordazepam.Approved
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Diphenhydramine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Diphenhydramine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Diphenhydramine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenhydramine.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olopatadine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Diphenhydramine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Orbifloxacin.Vet Approved
OrphenadrineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Otilonium.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxaflozane.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Oxaliplatin.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxaprotiline.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenhydramine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxitropium.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Oxolinic acid.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenhydramine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxyphencyclimine.Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Diphenhydramine.Investigational, Withdrawn
OxyphenoniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxyphenonium.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diphenhydramine.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Paliperidone.Approved
PalmidrolThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Palmidrol.Experimental, Nutraceutical
PancuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Papaverine.Approved, Investigational
ParaldehydeDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paramethadione.Approved
ParaoxonThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Paraoxon.Experimental
PargylineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pasireotide.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pefloxacin.Approved
PenbutololThe metabolism of Penbutolol can be decreased when combined with Diphenhydramine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Diphenhydramine.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Penthienate.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenhydramine.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Diphenhydramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Diphenhydramine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Diphenhydramine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pheniramine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Diphenhydramine.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phensuximide.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Physostigmine.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Diphenhydramine.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pinazepam.Experimental
PindololThe metabolism of Pindolol can be decreased when combined with Diphenhydramine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pipemidic acid.Experimental
PipenzolateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipenzolate.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Piperidolate.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Piromidic acid.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Diphenhydramine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Diphenhydramine.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Diphenhydramine.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Poldine.Experimental
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Diphenhydramine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Diphenhydramine.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Diphenhydramine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Diphenhydramine.Approved, Investigational
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Diphenhydramine is combined with Potassium Chloride.Approved, Withdrawn
PracinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Pracinostat.Investigational
PractololThe metabolism of Practolol can be decreased when combined with Diphenhydramine.Approved
PramipexoleDiphenhydramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Diphenhydramine.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Diphenhydramine.Approved
PregabalinThe therapeutic efficacy of Diphenhydramine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prifinium.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenhydramine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Diphenhydramine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Progabide.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Diphenhydramine.Approved, Vet Approved
PromazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Diphenhydramine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Diphenhydramine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenhydramine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Diphenhydramine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Proxibarbal.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Diphenhydramine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Prulifloxacin.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Diphenhydramine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Quetiapine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Diphenhydramine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of constipation can be increased when Diphenhydramine is combined with Ramosetron.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Diphenhydramine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Diphenhydramine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenhydramine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Remoxipride.Approved, Withdrawn
ReposalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diphenhydramine.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Revefenacin.Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ribostamycin.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rilpivirine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Riluzole.Approved, Investigational
RimonabantThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Rimonabant.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenhydramine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Diphenhydramine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Diphenhydramine.Approved, Investigational
RivastigmineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rizatriptan.Approved
RociverineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rociverine.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Rolitetracycline.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Romifidine.Vet Approved
RopiniroleDiphenhydramine may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rosoxacin.Approved, Investigational
RotigotineDiphenhydramine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Diphenhydramine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Diphenhydramine.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rupatadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Diphenhydramine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Diphenhydramine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sarafloxacin.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Saredutant.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenhydramine.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Secretin human can be decreased when used in combination with Diphenhydramine.Approved
Secretin porcineThe therapeutic efficacy of Secretin porcine can be decreased when used in combination with Diphenhydramine.Approved
SelegilineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Diphenhydramine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sisomicin.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sitafloxacin.Experimental, Investigational
SLV319The risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with SLV319.Investigational
Sodium oxybateDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Diphenhydramine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Diphenhydramine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Diphenhydramine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Solifenacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Diphenhydramine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Diphenhydramine.Approved
SotalolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Diphenhydramine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideDiphenhydramine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sunitinib.Approved, Investigational
SurinabantThe risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with Surinabant.Investigational
SuvorexantDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TafenoquineThe metabolism of Tafenoquine can be decreased when combined with Diphenhydramine.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Talbutal.Approved, Illicit
TalinololThe metabolism of Talinolol can be decreased when combined with Diphenhydramine.Investigational
TalopramThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Talopram.Experimental
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Diphenhydramine resulting in a loss in efficacy.Approved
TandospironeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Tandutinib.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tasimelteon.Approved, Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Technetium Tc-99m ciprofloxacin.Investigational
Technetium Tc-99m tilmanoceptDiphenhydramine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Diphenhydramine.Approved, Investigational, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenhydramine.Approved, Investigational
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Diphenhydramine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Terodiline.Experimental
TertatololThe metabolism of Tertatolol can be decreased when combined with Diphenhydramine.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetracycline.Approved, Vet Approved
TetraethylammoniumThe serum concentration of Tetraethylammonium can be increased when it is combined with Diphenhydramine.Experimental, Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrodotoxin.Investigational
ThalidomideDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Diphenhydramine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiothixene.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thonzylamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiapride.Approved, Investigational
Tiemonium iodideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiemonium iodide.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tilidine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Timepidium.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Diphenhydramine.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Diphenhydramine is combined with Topiramate.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Toremifene.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Diphenhydramine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Diphenhydramine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Diphenhydramine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Diphenhydramine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tridihexethyl.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenhydramine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Diphenhydramine.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trimethadione.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trimethaphan.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Diphenhydramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Triptorelin.Approved, Vet Approved
TropatepineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Diphenhydramine.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trospium.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Tucidinostat.Investigational
TyrothricinThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Umeclidinium.Approved
ValerianThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Diphenhydramine.Approved
VareniclineDiphenhydramine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vinylbital.Experimental
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Diphenhydramine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Vorinostat.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Diphenhydramine is combined with WIN 55212-2.Experimental
XP19986The risk or severity of adverse effects can be increased when Diphenhydramine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenhydramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zolmitriptan.Approved, Investigational
ZolpidemDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.

US5260333
General References
  1. Raphael GD, Angello JT, Wu MM, Druce HM: Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006 Apr;96(4):606-14. [PubMed:16680933]
  2. Abdi A, Rose E, Levine M: Diphenhydramine overdose with intraventricular conduction delay treated with hypertonic sodium bicarbonate and i.v. lipid emulsion. West J Emerg Med. 2014 Nov;15(7):855-8. doi: 10.5811/westjem.2014.8.23407. Epub 2014 Sep 19. [PubMed:25493135]
  3. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]
  4. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456]
External Links
Human Metabolome Database
HMDB0001927
KEGG Drug
D00300
KEGG Compound
C06960
PubChem Compound
3100
PubChem Substance
46505484
ChemSpider
2989
BindingDB
50017674
ChEBI
4636
ChEMBL
CHEMBL657
Therapeutic Targets Database
DAP000490
PharmGKB
PA449349
IUPHAR
1224
Guide to Pharmacology
GtP Drug Page
HET
2PM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Diphenhydramine
ATC Codes
D04AA33 — Diphenhydramine methylbromideD04AA32 — DiphenhydramineR06AA02 — DiphenhydramineR06AA52 — Diphenhydramine, combinations
AHFS Codes
  • 04:04.04 — Ethanolamine Derivatives
  • 04:04.00 — First Generation Antihistamines
PDB Entries
2aot
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableTherapeutic Equivalence1
1CompletedBasic ScienceAllergic Rhinitis (AR)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceNasal Stuffiness1
1CompletedScreeningFibrosis1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPain1
1CompletedTreatmentRestless Legs Syndrome (RLS)1
1RecruitingDiagnosticPatients With Suspected Malignancies of the Pituitary Gland1
1RecruitingDiagnosticA Diagnosis of Any Resectable Lung or Pleural Nodule1
1RecruitingTreatmentDiseases of Oesophagus Stomach and Duodenum1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1RecruitingTreatmentNeoplasms Malignant1
1RecruitingTreatmentPompe's Disease1
1RecruitingTreatmentTransplantation, Liver1
1RecruitingTreatmentTumors, Solid1
1TerminatedNot AvailableHealthy Male Volunteers1
1TerminatedBasic ScienceDrug Metabolism, Poor, CYP2D6-RELATED1
1TerminatedTreatmentAlpha-1 Antitrypsin Deficiency1
1WithdrawnDiagnosticAbdominal Pain (AP) / Gallbladder disorders / Gallstone formation / Jaundice / Pancreatitis1
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
1, 2CompletedTreatmentLeukemia, Acute Lymphocytic (ALL) / Leukemia, Acute Myelogenous (AML) / Leukemia, Chronic Myelogenous (CML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentPost-Traumatic Headaches1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2RecruitingTreatmentLiver Transplant Recipients / Living Donor (of the Respective Liver Transplant Recipient)1
1, 2RecruitingTreatmentLung Cancers1
1, 2TerminatedTreatmentColo-rectal Cancer / Colon/Rectal Cancer / Colon/Rectal Cancer Rectal Cancer / Rectal Carcinoma1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentNephritis, Lupus1
2Active Not RecruitingTreatmentRenal Cancers1
2CompletedNot AvailableCancers / Tumors, Solid1
2CompletedSupportive CareStomatitis, Aphthous1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCerebrovascular Accident, Acute / Edema of the cerebrum1
2CompletedTreatmentChronic Idiopathic Urticaria1
2CompletedTreatmentDepression1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentLeukemia, Mast-Cell / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentLupus Erythematosus, Systemic1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentRejection, Transplant1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2CompletedTreatmentVulvodynia1
2RecruitingTreatmentAlcohol Dependence1
2RecruitingTreatmentCocaine-Related Disorders1
2RecruitingTreatmentHNSCC / HPV-Related Squamous Cell Carcinoma1
2RecruitingTreatmentPlasma Cell Myeloma2
2RecruitingTreatmentTransplant, Kidney1
2TerminatedSupportive CareNausea / Unspecified Childhood Solid Tumor, Protocol Specific / Vomiting1
2TerminatedTreatmentBlood and Marrow Transplant (BMT) / Diffuse Large B-Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphomas: Non-Hodgkin / Malignant Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentHepatitis B Chronic Infection1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2TerminatedTreatmentTransplantation, Kidney1
2, 3CompletedTreatmentLupus Erythematosus, Systemic1
2, 3CompletedTreatmentMalaria caused by Plasmodium falciparum1
2, 3CompletedTreatmentVesicular Stomatitis1
2, 3TerminatedTreatmentLupus Erythematosus, Systemic1
3CompletedTreatmentAcute Urticaria1
3CompletedTreatmentChronic Idiopathic Urticaria1
3CompletedTreatmentElective Caesarean Section Surgeries1
3CompletedTreatmentHeadaches / Intranasal Ketamine1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMigraines1
3CompletedTreatmentNephritis, Lupus1
3Not Yet RecruitingTreatmentMalaria caused by Plasmodium falciparum1
3RecruitingTreatmentAcute Urticaria1
3RecruitingTreatmentPost-Traumatic Headaches1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3Unknown StatusTreatmentSleeplessness1
3WithdrawnTreatmentCoughing / Inflammatory Reaction / Rhinitis1
4Active Not RecruitingSupportive CareAdjunct Anesthesia Medication / Colonoscopy1
4CompletedDiagnosticAsthma Bronchial1
4CompletedPreventionHypnotic / Specified Sedative1
4CompletedTreatmentBacterial Infections1
4CompletedTreatmentCough Reflex Sensitivity1
4CompletedTreatmentHeadaches1
4CompletedTreatmentMigraines2
4CompletedTreatmentMigrainous Headache / Nausea / Restlessness1
4CompletedTreatmentNasal Stuffiness1
4CompletedTreatmentExtra-pyramidal symptoms / Nausea1
4CompletedTreatmentNeurogenic Intermittent Claudication / Spinal Stenosis of Lumbar Region1
4CompletedTreatmentOccasional Sleeplessness1
4RecruitingTreatmentHeadaches1
4SuspendedTreatmentMigrainous Headache1
Not AvailableActive Not RecruitingOtherPain1
Not AvailableActive Not RecruitingScreeningAlcoholism1
Not AvailableCompletedBasic ScienceHyperalgesia1
Not AvailableCompletedBasic ScienceMemory, Long-Term / Memory, Short-Term1
Not AvailableCompletedOtherPain, Neuropathic1
Not AvailableCompletedPreventionGeneral Surgery / Pain1
Not AvailableCompletedPreventionHeadaches1
Not AvailableCompletedSupportive CareFocus of Study: Absorption of the Three Components in the Topical ABH Gel in Healthy Volunteers, and Determine if There Are Any Adverse Effects / Healthy Volunteers1
Not AvailableCompletedSupportive CareNausea / Vomiting1
Not AvailableCompletedTreatmentBenign Paroxysmal Positional Vertigo (BPPV)1
Not AvailableCompletedTreatmentEndometriosis1
Not AvailableCompletedTreatmentEndoscopy / Sedation therapy1
Not AvailableCompletedTreatmentHip Fracture Surgery / Post Operative Pain Control1
Not AvailableCompletedTreatmentItching1
Not AvailableCompletedTreatmentPain1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Depression / Disease, Chronic / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentAnxiety Disorders / Moods Disorders / Pain Disorders / Somatization Disorder1
Not AvailableRecruitingTreatmentMigrainous Headache1
Not AvailableSuspendedDiagnosticBulimia Nervosa (BN) / Catechol-O-methyltransferase / Dopamine / Eating Disorders / Reward1
Not AvailableTerminatedNot AvailablePain, Chronic1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentPrimary Headaches (Includes Migraines, Tension, Cluster Headaches)1
Not AvailableUnknown StatusSupportive CareEndoscopic Retrograde Cholangiopancreatography (ERCP) / Endoscopic Ultrasound (EUS)1
Not AvailableWithdrawnTreatmentPost Operative Nausea and Vomiting (PONV) / Rescue Emetic Therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advance Pharmaceutical
  • Advent Pharmaceuticals Inc.
  • Amend
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Auriga Pharmaceuticals LLC
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Bergen Brunswig
  • Bioniche Pharma
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Chattem Chemicals Inc.
  • Concord Labs
  • Consolidated Midland Corp.
  • Contract Pharm
  • CVS Pharmacy
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • DispenseXpress Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Equaline Vitamins
  • Fusion Pharmaceuticals LLC
  • General Injectables and Vaccines Inc.
  • GlaxoSmithKline Inc.
  • Goldline Laboratories Inc.
  • Group Health Cooperative
  • Hawthorn Pharmaceuticals
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kraft Pharmaceutical Co. Inc.
  • Liberty Pharmaceuticals
  • Lnk International Inc.
  • Major Pharmaceuticals
  • Martin Surgical Supply
  • McNeil Laboratories
  • Medique Products
  • Medtech Labs
  • Merit Pharmaceuticals
  • Midlothian Labs
  • Mississippi State Dept Health
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nexgen Pharma Inc.
  • North Safety Products
  • Nucare Pharmaceuticals Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pharmedix
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Procter & Gamble
  • Provident Pharmaceuticals LLC
  • Remedy Repack
  • Rite Aid Corp.
  • River's Edge Pharmaceuticals
  • Rugby Laboratories
  • Sandhills Packaging Inc.
  • Scientific Laboratories Inc.
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vangard Labs Inc.
  • Walgreen Co.
Dosage forms
FormRouteStrength
Capsule; kitOral
CreamTopical20 mg/mL
CreamTopical2 mL/100mL
PowderOral25 mg/1
LiquidOral12.5 mg
Tablet, chewableOral12.5 mg/1
Tablet, film coatedOral25 mg/1
SolutionOral12.5 mg
GelTopical2 g/100g
CreamTopical2.0 %
PatchTopical
Kit
TabletOral25 mg
Tablet, coatedOral25 mg/1
Tablet, chewableOral12.5 mg
LiquidTopical
LiquidOral6.25 mg
CreamTopical2 %
ElixirOral12.5 mg
GelTopical20 mg/mL
Tablet, chewableOral25 mg
GelTopical2 %
TabletOral25 mg/250mg
StripOral25 mg
LotionTopical
SuspensionTopical
SyrupOral6.25 mg
TabletOral19 mg
StripOral19 mg
SuspensionOral
TabletOral12.5 mg/1
LiquidOral12.5 mg/5mL
Kit; tabletOral
OintmentTopical
KitTopical
KitOral
TabletOral38.0 mg
Capsule, coatedOral25 mg/1
Injection, solutionIntravenous50 mg/mL
Capsule, liquid filledOral20 mg/1
Capsule, gelatin coatedOral25 mg/1
LiquidIntravenous50 mg
ElixirOral12.5 mg/5mL
ElixirOral25 mg/10mL
InjectionIntramuscular50 mg/mL
InjectionIntramuscular; Intravenous50 mg/mL
Injection, solutionIntramuscular; Intravenous50 mg/mL
SolutionOral25 mg/10mL
SolutionOral50 mg/20mL
LiquidIntramuscular; Intravenous50 mg
KitOral; Topical
TabletOral
Tablet, film coatedOral
LiquidOral50 mg/30mL
SolutionOral50 mg/40mL
KitOral
Aerosol, sprayTopical
Capsule, coatedOral
Tablet, coatedOral
PowderOral
Capsule, liquid filledOral
LiquidTopical20.3 g/L
SprayTopical2 g/100mL
GelTopical2.03 g/100g
AerosolTopical
SolutionTopical
GelTopical2 g/100mL
StripOral12.5 mg
TabletOral12.5 mg
Tablet, orally disintegratingOral12.5 mg/1
LinimentTopical
CreamTopical
Capsule, gelatin coatedOral50 mg/1
Kit
LozengeOral25 mg
StripOral
TabletOral50 mg/1
CapsuleOral25 mg
SolutionOral50 mg
CapsuleOral50 mg/1
Tablet, film coatedOral50 mg/1
Capsule, liquid filledOral50 mg/21
SolutionOral
TabletOral50 mg
CapsuleOral
Capsule, gelatin coatedOral
ElixirOral2.5 mg
SyrupOral12.5 mg/5mL
GelTopical20.5 mg/mL
SprayTopical
LiquidOral
PlasterTopical
SolutionIntramuscular; Intravenous50 mg
GelTopical.2 g/10mL
Capsule, liquid filledOral50 mg/1
Capsule, liquid filledOral25 mg/1
TabletOral25 mg/1
Tablet, coatedOral50 mg/1
GelTopical
GelTopical20 mg/g
SprayTopical20 mg/mL
Powder, for solutionOral
SyrupOral
CapsuleOral25 mg/1
SolutionOral50 mg/30mL
CapsuleOral50 mg
Tablet, chewableOral25 mg/1
LiquidOral6.25 mg/mL
SolutionOral12.5 mg/5mL
LiquidOral25 mg/10mL
Capsule, gelatin coatedOral50 mg/21
Granule, for solutionOral
SprayTopical2.0 %
LiquidOral50 mg
Prices
Unit descriptionCostUnit
DiphenhydrAMINE HCl 100 50 mg capsule Bottle13.99USD bottle
Diphenhydramine 50 mg/ml3.94USD ml
Diphenhydramine 50 mg/ml vial1.69USD ml
DiphenhydrAMINE HCl 50 mg/ml vial1.44USD vial
Dytan 25 mg tablet chewable1.37USD tablet
Benadryl 50 mg/ml vial1.36USD ml
Diphenmax 25 mg tablet1.24USD tablet
Benadryl allergy 25 mg strips0.45USD strip
Unisom sleep aid tablet0.34USD tablet
Sleep-eze 3 tablet0.29USD tablet
Compoz 50 mg tablet0.27USD tablet
Sominex max str 50 mg caplet0.27USD caplet
Benadryl allergy fastmelt tablet0.26USD tablet
Unisom 25 mg sleeptabs0.25USD tablet
Unisom 50 mg sleepgels0.25USD each
Unisom sleepmelts 25 mg tablet0.24USD tablet
Nytol 25 mg tablet0.23USD tablet
Benadryl allergy-sinus caplet0.22USD caplet
Compoz 25 mg gelcap0.2USD capsule
Benadryl allergy 25 mg softgel0.19USD softgel capsule
Benadryl allergy 25 mg ultratab0.19USD tablet
Benadryl allergy-cold kapgels0.19USD each
Benadryl allergy-sinus kapgels0.19USD each
Benadryl-d allergy-sinus ultratab0.19USD tablet
Diphenhydramine hcl powder0.17USD g
Eql allergy 25 mg tablet0.17USD tablet
Nighttime sleep aid 25 mg cplt0.17USD caplet
Banophen anti-itch 2% cream0.16USD g
Benadryl itch relief stick0.16USD ml
Sominex 25 mg tablet0.16USD tablet
Benadryl allergy 25 mg kapgels0.15USD each
Allergy 25 mg tablet0.14USD tablet
Benadryl 25 mg kapseals0.14USD each
Benadryl itch stopping crm0.14USD g
DiphenhydrAMINE HCl 25 mg capsule0.13USD capsule
Diphenhist with zinc cream0.12USD g
Ra allergy 25 mg tablet0.12USD tablet
CVS Pharmacy allergy 25 mg tablet0.11USD tablet
Diphenhydramine 25 mg minitab0.11USD tablet
Simply sleep 25 mg caplet0.11USD caplet
Sleep ii tablet0.11USD tablet
Diphenhydramine 50 mg capsule0.1USD capsule
Benadryl 2% spray0.09USD ml
Diphenhist 50 mg tablet0.09USD tablet
Genahist 25 mg tablet0.09USD tablet
Ra sleep tablet0.09USD tablet
Banophen 25 mg tablet0.08USD tablet
Wal-dryl anti-itch spray0.08USD ml
CVS Pharmacy allergy 25 mg caplet0.07USD caplet
Nighttime sleep aid 25 mg caplet0.07USD caplet
CVS Pharmacy itch relief spray0.06USD ml
Diphen 25 mg capsule0.06USD capsule
Diphenhist 25 mg caplet0.06USD caplet
Benadryl anti-itch 0.45% gel0.05USD g
Diphenhydramine 50 mg caplet0.05USD caplet
Benadryl itch stopping gel0.04USD g
Child benadryl-d aller-sin liquid0.04USD ml
Diphenhydramine 25 mg capsule0.04USD capsule
Vicks 44d cough & head liquid0.03USD ml
Vicks 44e cough & chest liquid0.03USD ml
Banophen allergy liquid0.02USD ml
Diphenhydramine 25 mg tablet0.02USD tablet
Ra anti-tussive dm syrup0.02USD ml
Siladryl 12.5 mg/5 ml liquid0.02USD ml
Silphen cough syrup0.02USD ml
Silphen dm cough syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8883849No2002-01-172022-01-17Us
US9155718No2002-01-172022-01-17Us
US8263647No2002-05-302022-05-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)161-162Martin, H., Hafliger, F.,Gatzi, K.and Grob, A.; U.S. Patent 2,397,799; April 2,1946; assigned to J.R. Geigy AG, Switzerland. Rieveschl, G. Jr.; U.S. Patent 2,421,714; June 3,1947; assigned to Parke, Davis & Co. Rieveschl, G. Jr.; U.S. Patent 2,427,878; September 23,1947; assigned to Parke, Davis & Company.
boiling point (°C)150-165 °C at 2.00E+00 mm HgPhysProp
water solubility3060 mg/L (at 37 °C)BEILSTEIN
logP3.27HANSCH,C ET AL. (1995)
pKa8.98SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0752 mg/mLALOGPS
logP3.44ALOGPS
logP3.65ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.93 m3·mol-1ChemAxon
Polarizability29.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9898
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8744
P-glycoprotein substrateSubstrate0.6211
P-glycoprotein inhibitor INon-inhibitor0.6632
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterInhibitor0.7752
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6173
CYP450 1A2 substrateInhibitor0.8306
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9039
CYP450 3A4 inhibitorNon-inhibitor0.934
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7293
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6495
BiodegradationNot ready biodegradable0.9253
Rat acute toxicity2.7846 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.6318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9100000000-7b9eb1f702c76f6b6062
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9200000000-b9014c8fc8ccbba24163
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-0006-0090000000-a71e531b49571f09ab25
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-00kk-0980000000-cce91896f34562beeffa
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-001i-1900000000-4c29bd5e0eab94596eaa
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-0a4i-9100000000-ab642e8f86de11af896c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000t-0910000000-3576ca5ec77ab87354ec
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-0ccd6de9ca58593fd490
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-3568aae4c27ffe333c0e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-22e0c745355c836f1535
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-6bb69a66a343440c64f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-1b87d83415d22bb17f1b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-0900000000-50251362d768cd1b1c4f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-0900000000-9f37a733a05f5b01d313
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0900000000-7d73b95ed09ea2d72260
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-2900000000-1666a8ab5a6d81c0bd01
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-3f31841d858381760f03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-de872e048c7e12cef490
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-de872e048c7e12cef490
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0900000000-789a4a3fe118d5bf2456
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2900000000-8ef94659f614b9ff24ca
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-2950000000-7c7a9841f2f0b6428d69
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Benzylethers / Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Benzylether / Tertiary aliphatic amine / Tertiary amine / Ether / Dialkyl ether / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, ether (CHEBI:4636) / a small molecule (CPD-10890)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Piao H, Nagai S, Tsurumaki T, Niki T, Higuchi H: Potentiation by neuropeptide Y of histamine H1 receptor-mediated contraction in rat blood vessels. Vascul Pharmacol. 2007 Apr;46(4):260-70. Epub 2006 Oct 27. [PubMed:17169617]
  3. Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8. [PubMed:16702624]
  4. Hasala H, Moilanen E, Janka-Junttila M, Giembycz MA, Kankaanranta H: First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc. 2007 Jan-Feb;28(1):79-86. [PubMed:17390763]
  5. Wang Z, Woolverton WL: Self-administration of cocaine-antihistamine combinations: super-additive reinforcing effects. Eur J Pharmacol. 2007 Feb 28;557(2-3):159-60. Epub 2006 Dec 1. [PubMed:17196194]
  6. Ishikawa T, Takechi K, Rahman A, Ago J, Matsumoto N, Murakami A, Kamei C: Influences of histamine H1 receptor antagonists on maximal electroshock seizure in infant rats. Biol Pharm Bull. 2007 Mar;30(3):477-80. [PubMed:17329841]
  7. Havas TE, Cole P, Parker L, Oprysk D, Ayiomamitis A: The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topical histamine provocation. J Allergy Clin Immunol. 1986 Nov;78(5 Pt 1):856-60. [PubMed:2878016]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Liu H, Zheng Q, Farley JM: Antimuscarinic actions of antihistamines on the heart. J Biomed Sci. 2006 May;13(3):395-401. [PubMed:16453179]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:48